Z. Kartasis

发表

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

M. Dimopoulos, T. Economopoulos, A. Symeonidis, 2010, European journal of haematology.

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

M. Dimopoulos, K. Konstantopoulos, E. Kastritis, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

M. Dimopoulos, P. Sonneveld, P. Morel, 2013, Blood.

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

P. Korkolopoulou, E. Hatzimichael, K. Giannikou, 2010, Haematologica.

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2014 .

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

M. Dimopoulos, T. Economopoulos, E. Kastritis, 2009, Leukemia.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, American journal of hematology.

CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: ﬁ nal analysis of a phase 2 study after a minimum follow-up of 6 years

M. Dimopoulos, P. Sonneveld, P. Morel, 2017 .

Prognostication of the high-risk WM patient.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2011, Clinical Lymphoma, Myeloma & Leukemia.

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2009, Leukemia research.

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

M. Dimopoulos, S. Giannouli, E. Hatzimichael, 2014, Leukemia.

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

M. Dimopoulos, P. Sonneveld, P. Morel, 2009 .

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

M. Dimopoulos, E. Hatzimichael, E. Kastritis, 2012, European journal of haematology.

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

M. Dimopoulos, K. Konstantopoulos, E. Hatzimichael, 2011 .

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

M. Dimopoulos, S. Giannouli, E. Hatzimichael, 2017, European journal of haematology.

Amifostine Stimulates the Formation of Hematopoietic Bone Marrow Progenitors from B-Cell Chronic Lymphocytic Leukemia

D. Margaritis, I. Kotsianidis, G. Bourikas, 2004, Acta Haematologica.

Assessment of platelet adhesiveness and aggregation in mild acute pancreatitis using the PFA-100 system.

G. Bourikas, K. Mimidis, M. Baka, 2004, JOP : Journal of the pancreas.

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group

M. Dimopoulos, E. Hatzimichael, E. Kastritis, 2011 .

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

M. Dimopoulos, E. Kastritis, E. Terpos, 2012 .

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.